Myelodysplastic Syndromes (MDS)

High Risk MDS to AML Webinar

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Lacey Williams, MD
In this webinar, Dr. Lacey Williams discusses the diagnosis of High Risk MDS and treatment options available to patients.

Low Risk MDS Webinar

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Jose Martinez, MD, PhD
In this webinar, Dr. Jose Martinez discuesse the diagnosis of Low Risk MDS and treatment options available to patients.

Curing the Incurable: TP53 Mutated Myeloid Neoplasms

Original Publication Date
Article Source
External Web Content
Abstract The TP53 gene ensures genetic fidelity by regulating cell cycle kinetics and apoptosis. In myeloid neoplasms, TP53 mutation is witnessed in 13% of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Alterations in TP53 or its respective protein is…

IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML

Original Publication Date
Article Source
External Web Content
Immunohistochemistry (IHC) could represent a biomarker for the early detection of TP53 mutations and for the prediction of a TP53 allelic state in patients with myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML), according to data from an observational trial…

A clinical guide to TP53 mutations in myeloid neoplasms

Original Publication Date
Article Source
External Web Content
TP53 mutations are found in 10-15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is a key determinant of clinical outcomes, with multi-hit TP53 mutant myeloid neoplasms having a very poor prognosis…
Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.